Establishing mesothelioma patient-derived organoid models from malignant pleural effusions
Open Access
- 28 March 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 191, 107542
Abstract
No abstract availableKeywords
Funding Information
- icare
- icare Foundation
- Flinders Foundation
This publication has 47 references indexed in Scilit:
- The cytological features of effusions with mesothelioma in situ: A report of 9 casesDiagnostic Cytopathology, 2023
- Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platformIn Vitro Cellular & Developmental Biology - Animal, 2021
- Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesCell Reports, 2020
- Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapyBritish Journal of Surgery, 2019
- Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesotheliomaJournal of Proteomics, 2019
- Patient-derived tumor organoids for prediction of cancer treatment responseSeminars in Cancer Biology, 2018
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018
- Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutationsLung Cancer, 2018
- A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityCell, 2018
- Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal MesotheliomaCancer Microenvironment, 2010